News Lilly, Regeneron among firms chosen for FDA fast plant pilot Eli Lilly, Regeneron, and five other drugmakers will take part in an FDA pilot designed to make it quicker and easier to set up manufacturing plants.
News EFPIA report adds to pressures on EU drug pricing policy Pharma trade body EFPIA says access to new medicines is worsening across Europe, as it makes the socioeconomic case for spending more on novel drugs.
News HHS details plan to regain the US's edge in clinical trials The US launches a concerted effort to "restore American leadership in clinical trials" as it deals with the emergence of China as a global R&D hub.
News US launches probe of German 'underpayment' for medicines A Section 301 probe by the US Trade Representative into Germany's medicine pricing and reimbursement policies raises the threat of punitive tariffs.
News FDA prior knowledge guide seeks to speed cell, gene therapy The FDA has laid out a framework to use 'prior knowledge' on manufacturing, non-clinical, and clinical data to support cell and gene therapy filings.
News SCOTUS won't hear pharma's IRA complaints The US Supreme Court has refused to consider lawsuits from pharma groups challenging Medicare's drug pricing negotiation powers.
News Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer Eli Lilly's imlunestrant (Inluriyo) for breast cancer has received a new FDA approval, in combination with CDK4/6 inhibitor abemaciclib (Verzenio).
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.